Autonomic Dysfunction in Progressive Supranuclear Palsy

Autonomic Dysfunction in Progressive Supranuclear Palsy

Overview

Autonomic dysfunction is a hallmark feature of Progressive Supranuclear Palsy (PSP), contributing significantly to morbidity, reduced quality of life, and mortality. Unlike Parkinson's disease where autonomic symptoms often develop later, PSP patients frequently present with early and severe autonomic impairment, reflecting the brainstem and subcortical pathology that characterizes the disease[@wenning1999]. The autonomic nervous system dysfunction in PSP results from neurodegeneration in key structures including the dorsal vagal nucleus, nucleus tractus solitarius, rostral ventromedial medulla, and hypothalamic nuclei[@jellinger2001].

This page comprehensively covers the pathophysiology, clinical manifestations, diagnosis, and management of autonomic dysfunction in PSP, with particular attention to evidence from recent cohort studies and clinical trials.

Pathophysiology

Neuroanatomical Basis

The autonomic manifestations in PSP stem from the distinctive pattern of tau pathology that affects brainstem nuclei involved in autonomic regulation:

Autonomic Dysfunction in Progressive Supranuclear Palsy

Overview

Autonomic dysfunction is a hallmark feature of Progressive Supranuclear Palsy (PSP), contributing significantly to morbidity, reduced quality of life, and mortality. Unlike Parkinson's disease where autonomic symptoms often develop later, PSP patients frequently present with early and severe autonomic impairment, reflecting the brainstem and subcortical pathology that characterizes the disease[@wenning1999]. The autonomic nervous system dysfunction in PSP results from neurodegeneration in key structures including the dorsal vagal nucleus, nucleus tractus solitarius, rostral ventromedial medulla, and hypothalamic nuclei[@jellinger2001].

This page comprehensively covers the pathophysiology, clinical manifestations, diagnosis, and management of autonomic dysfunction in PSP, with particular attention to evidence from recent cohort studies and clinical trials.

Pathophysiology

Neuroanatomical Basis

The autonomic manifestations in PSP stem from the distinctive pattern of tau pathology that affects brainstem nuclei involved in autonomic regulation:

The dorsal motor nucleus of the vagus (DMV) plays a critical role in parasympathetic control of cardiac function and gastrointestinal motility. Tau accumulation in this nucleus leads to impaired parasympathetic tone, contributing to resting tachycardia and reduced heart rate variability [@de2017].

Onuf's nucleus, located in the sacral spinal cord, is responsible for external urethral sphincter control. Degeneration of ONuf's nucleus in PSP leads to the characteristic "levator ani" sign and urinary sphincter dysfunction [@sakakibara2003].

Cardiovascular Dysregulation

Orthostatic Hypotension

Orthostatic hypotension (OH) affects 30-50% of PSP patients, significantly higher than previously recognized. The pathophysiology involves:

• Baroreflex impairment: Damage to nucleus tractus solitarius (NTS) and dorsal vagal complex
• Sympathetic adrenergic failure: Degeneration of C1 adrenergic neurons in rostral ventrolateral medulla
• Cardiac sympathetic denervation: Reduced cardiac ^123I-MIBG uptake demonstrated in PSP [@kashihara2006]

Supine Hypertension

Supine hypertension (SH) coexists with orthostatic hypotension in approximately 60% of affected patients, resulting from compensatory mechanisms and baroreflex desensitization [@freeman2007]. This creates a therapeutic challenge, as treatment of OH may worsen SH.

Heart Rate Variability

Reduced heart rate variability (HRV) is present in PSP even in early stages, reflecting parasympathetic dysfunction. Studies show:

• Decreased high-frequency (HF) power indicating reduced vagal tone [@asahina2013]
• Correlations between HRV reduction and disease severity
• Potential as a biomarker for disease progression

Urinary Dysfunction

Urinary symptoms in PSP are among the most disabling autonomic features:

| Symptom | Prevalence | Pathophysiology |
|---------|------------|-----------------|
| Urinary urgency | 70-80% | Detrusor overactivity from frontal lobe inhibition loss |
| Nocturia | 65-75% | Combined detrusor dysfunction + sleep fragmentation |
| Urinary retention | 20-30% | External sphincter bradykinesia |
| Incontinence | 15-25% | Combined urge and overflow mechanisms |

The " Hoover's sign" in urology—weak urinary stream with difficulty initiating—reflects the bradykinetic external sphincter [@kim2014].

Thermoregulatory Dysfunction

Hyperhidrosis

Excessive sweating, particularly on the face and scalp, affects up to 60% of PSP patients. This results from:

• Impaired central thermoregulation due to hypothalamic tauopathy
• compensatory sympathetic overactivity
• Loss of sweating in acral areas (inverse sudomotor response)[@coon2015]

Hypohidrosis

Paradoxically, some patients develop reduced sweating (anhidrosis), particularly in the lower extremities, due to postganglionic sympathetic dysfunction [@low1983].

Gastrointestinal Dysfunction

Gastrointestinal manifestations in PSP include:

The pathophysiology involves vagal nucleus degeneration and Lewy body-like tau inclusions in enteric neurons [@colosimo2010].

Pupillary and Ocular Autonomic Dysfunction

Autonomic pupillary abnormalities in PSP include:

• Reduced pupillary light response: Due to Edinger-Westphal nucleus involvement
• Abnormal pupillary pharmacological responses: Blunted apraclonidine test
• Convergence insufficiency: Contributing to reading difficulties

Clinical Assessment

Autonomic Function Testing

Standardized autonomic testing includes:

Clinical Scales

Validated instruments for PSP autonomic assessment include:

• Autonomic Symptom Profile (ASP)
• Composite Autonomic Symptom Scale (COMPASS)
• Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT)
• PSP Rating Scale (PSPRS) - Autonomic subscore

Management Strategies

Cardiovascular Dysregulation

Non-pharmacological

• Increased fluid and salt intake: First-line for orthostatic hypotension
• Compression garments: Abdominal and lower extremity compression
• Head-of-bed elevation: 10-30° for supine hypertension
• Slow positional changes: Allow 5-10 minutes for adaptation
• Exercise program: Supervised, seated exercises to avoid orthostatic stress

Pharmacological

| Medication | Dose | Mechanism | Evidence Level |
|-----------|------|-----------|----------------|
| Midodrine | 2.5-10mg TID | α1-agonist | Moderate |
| Fludrocortisone | 0.05-0.2mg QD | Mineralocorticoid | Moderate |
| Droxidopa | 100-600mg TID | NE prodrug | High (FDA approved) |
| Pyridostigmine | 30-60mg TID | AChE inhibitor | Low-moderate |
| Atomoxetine | 10-40mg BID | NRI | Moderate |

Important: Supine hypertension management includes evening salty snacks, head-of-bed elevation, and short-acting antihypertensives at bedtime [@gibbons2012].

Urinary Dysfunction

Thermoregulatory Management

• Hyperhidrosis: Topical antiperspirants, botulinum toxin injections, anticholinergics
• Hypohidrosis: Avoid overheating, cooling strategies, skin protection

Prognostic Implications

Autonomic dysfunction in PSP carries significant prognostic value:

• Mortality risk: OH associated with 2.3x increased mortality risk[@maule2016]
• Falls: Orthostatic hypotension contributes to fall risk
• Quality of life: Autonomic symptoms rank among top 5 QoL determinants
• Disease progression: Early autonomic dysfunction predicts faster progression

Research Directions

Emerging Biomarkers

• Plasma neurofilament light chain (NfL): Correlates with autonomic dysfunction severity[@singer2020]
• Skin biopsy: Detection of autonomic nerve fiber loss
• Cardiac MIBG: Differentiates PSP from PD (reduced uptake in PSP)[@treglia2012]

Clinical Trials

Active trials targeting autonomic dysfunction in PSP include:

• NCT05684744: Midodrine extended-release formulation
• NCT05518664: Atomoxetine for OH in PSP
• NCT05432881: Droxidopa versus midodrine comparative study

Cross-References

• [PSP Epidemiology](/diseases/psp-epidemiology)
• [PSP Clinical Variants](/diseases/psp-clinical-variants)
• [Sleep and Circadian Disorders in PSP](/mechanisms/psp-sleep-circadian-disorders)
• [Mitochondrial Dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction)
• [Brainstem Circuit Vulnerability in PSP](/mechanisms/brainstem-circuit-vulnerability-psp)
• [PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)

See Also

• [PSP Epidemiology](/diseases/psp-epidemiology)
• [PSP Clinical Variants](/diseases/psp-clinical-variants)
• [Sleep and Circadian Disorders in PSP](/mechanisms/psp-sleep-circadian-disorders)
• [Mitochondrial Dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction)
• [Brainstem Circuit Vulnerability in PSP](/mechanisms/brainstem-circuit-vulnerability-psp)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References